Dr. Reddy`s Laboratories gains after getting EIR for API manufacturing facility in Telangana
Dr. Reddy's Laboratories is currently trading at Rs 1225.50, up by 13.85 points or 1.14% from its previous closing of Rs 1211.65 on the BSE.
The scrip opened at Rs 1211.20 and has touched a high and low of Rs 1227.00 and Rs 1208.40 respectively. So far 12477 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1420.20 on 21-Aug-2024 and a 52-week low of Rs 1025.90 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 1232.40 and Rs 1182.40 respectively. The current market cap of the company is Rs 101735.52 crore.
The promoters holding in the company stood at 26.64%, while Institutions and Non-Institutions held 52.07% and 10.26% respectively.
Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from United States Food & Drug Administration (USFDA) for its API manufacturing facility (CTO 5) in Miryalaguda, Telangana, India. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
